Alps Group Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALPS research report →
Price Chart
About the company
Alps Group Inc. operates as a comprehensive biotechnology firm, delivering a wide array of services ranging from groundbreaking research and development to direct medical care and health optimization initiatives, with a primary focus on cutting-edge therapeutic solutions. The organization is committed to cultivating a just and balanced healthcare system, ensuring broad availability of early detection, disease prevention, and individualized treatment approaches.
- CEO
- Seng Kong Tham
- IPO
- 2025
- Employees
- 2
- HQ
- Kuala Lumpur, WP, MY
Get TickerSpark's AI analysis on ALPS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $53.25M
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 15.80
- P/B
- -0.38
- EV/EBITDA
- -0.79
- Div Yield
- 0.00%
- Gross Margin
- 38.60%
- Op Margin
- -1983.07%
- Net Margin
- -2004.52%
- ROE
- 1082.61%
- ROIC
- -3563.18%
Latest fiscal year · YoY change
- Revenue
- $3.37M+0.0%
- Gross Profit
- $1.30M+0.0%
- Op Income
- $-66,849,980
- Net Income
- $-67,573,060-2588.3%
- EPS
- $-14.64-2052.9%
- OCF Growth
- -60.1%
- FCF Growth
- -55.5%
- 52W High
- $2.90
- 52W Low
- $0.23
- 50D MA
- $0.51
- 200D MA
- $0.84
- Beta
- -0.06
- RSI (14)
- 32
- Avg Volume
- 117.88K
No earnings-call transcripts are available for ALPS yet.
- Free Float
- 100.0%
- Shares Outstanding
- 166.40M
- Float Shares
- 166.40M
of shares held by institutions
10 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Skyview Investment Advisors, LLC | 10.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Lee Hee Hang | other | 0 |
| Mar 18, 26 | Poh Chit Laa | other | 0 |
| Mar 18, 26 | Chua Boon Ping | other | 0 |
| Mar 18, 26 | Chew Yoke Ling | other | 0 |
| Mar 18, 26 | Cheing Lye-Ping | other | 0 |
| Mar 18, 26 | Mohamed Suleiman bin | other | 0 |
| Mar 18, 26 | Manickam Ravichandran | other | 0 |
| Mar 18, 26 | Low Wei Sim | other | 0 |
| Mar 18, 26 | Tham Seng Kong | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALPS coverage
Recent articles, reports, and earnings notes.
No research on ALPS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALPS report →ALPS Corporation Goes Live on OneShield Market Solutions to Power Lawyers' Professional Liability Operations for LawyerCare
businesswire.com · Aug 18
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 7
ALPS Ties Fund Growth to Distribution Discipline
etftrends.com · Jul 24
Small Cap Quality Over Size: Why ALPS OUSM Deserves a Look
etftrends.com · Jun 24
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
globenewswire.com · Jun 23
ETFs for Investors Seeking Balance Amid Ceasefire Optimism
zacks.com · Jun 12
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
globenewswire.com · Jun 9
Love the AI Story but Hate the Concentration Risk? Consider ETFs
zacks.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.